Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease

• Status: Recruiting
• Trial end date: 2022-04-30
• Target enrollment: 0
• Participant gender: All

Summary

This was a randomized, single-blind, parallel, placebo-controlled clinical trial assessing the efficacy of neuronavigational TBS among patients with AD. Fourty late-onset AD were included in the study, all the patients were divided into TBS groups and drug treatment group. Drug intervention group AD patients with drug regimen (donepezil 5mg / d) and primary care guidance, once every three months follow-up. TBS group is treated with TBS (a course of treatment every 3 months); after completing 4 treatments/follow-ups a year, evaluate the changes in MoCA, other clinical symptoms and multi-domain cognition tests, and brain Changes in structure and function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anhui Medical University

Criteria

Inclusion Criteria:

• Subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria.

• Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia

• CDR score ≤ 2

• Subject under treatment by IAChE for at least 3 Weeks.

• psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months

Exclusion Criteria:

• CDR > 2

• Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).

• Page 5 of 6 [DRAFT] -

• History of head injury,stroke,or other neurologic disease.

• Organic brain defects on T1 or T2 images.

• History of seizures or unexplained loss of consciousness.

• Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.

• Family history of medication refractory epilepsy.

• History of substance abuse within the last 6 months.